AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05590975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACT Intervention
Description: PACT Intervention is a group based session delivered by Peer supporters and adult coaches on PACT module. There will be 10 sessions, one per week for 90 to 120 minutes each.
Study NCT04345562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin preparation patterns with ChloraPrep 2 x 26 mL single
Description: 2 different patterns of skin preparation
Study NCT04693559 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: secondary alveolar bone graft
Description: Under general anaesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will made on both the sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will dissected. Next, the bone particles will implanted into the bone defect. The cleft site will closed without tension by advancement of the gingival flaps
Study NCT04693559 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: harvesting of the autogenous bone graft
Description: osteotome and then cut into small bone granules. The bone granules will then carefully placed into a syringe and pressed to its densest state by pushing the plunger
Study NCT04693559 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nanocrystalline Hydroxyapatite
Description: Nanocrystalline Hydroxyapatite will be used to fill the alveolar defect
Study NCT06123078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaCBT
Description: Culturally adapted Self help guide and modules total eight 80 hour session per week
Study NCT05928403 — intervention group
Intervention type: OTHER
Intervention: total knee prosthesis
Description: Comparison of three cohorts on the return to sport of patients after total knee prosthesis according to the type of prosthesis
Study NCT05161923 — intervention group
Intervention type: PROCEDURE
Intervention: Per oral endoscopy myotomy
Description: The per-oral endoscopic myotomy, or POEM, is a minimally invasive surgical procedure for the treatment of achalasia wherein the inner circular muscle layer of the lower esophageal sphincter is divided through a submucosal tunnel.\[1\] This enables food and liquids to pass into the stomach, a process that is impaired in achalasia. The tunnel is created, and the myotomy performed, using a flexible endoscope, meaning the entire procedure can be done without external incisions.
Study NCT05991102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency electromagnetic field treatment
Description: Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
Study NCT05431543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine+Brimonidine combination ophthalmic solution
Description: LNZ101-combination ophthalmic solution
Study NCT05431543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine ophthalmic solution
Description: LNZ100- aceclidine ophthalmic solution
Study NCT05431543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle proprietary ophthalmic solution
Description: Proprietary Vehicle ophthalmic solution
Study NCT03127267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib (4.5)
Description: Masitinib (titration to 4.5 mg/kg/day)
Study NCT05306587 — intervention group
Intervention type: DRUG
Intervention: Darzalex
Description: Investigate the home administration of Darzalex SC reported by both patients and healthcare professionals compared to the hospital administration setting.
Study NCT04303559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eloctate Injectable Product
Description: This is a factor VIII-Fc fusion protein.
Study NCT04303559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab Injection [Hemlibra]
Description: This is a bispecific monoclonal antibody FVIII mimic.
Study NCT05393635 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ITIL-168
Description: ITIL-168 is a cell therapy product derived from a participant's own TILs. A portion of tumor is resected to make a personalized ITIL-168 product. If appropriate, participants may receive bridging therapy after recovering from the tumor resection during ITIL-168 manufacturing. Once ITIL-168 has been made, the participant is treated with up to 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.~Drug: Pembrolizumab Participants will receive 1 dose of pembrolizumab following tumor resection prior to receiving ITIL-168, and additional doses for up to a year after ITIL-168 infusion.
Study NCT05809609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who fail to respond to at least two antidepressant trials of adequate dose and duration.
Study NCT05809609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention (placebo)
Description: Placebo injection (0.9% sodium chloride)
Study NCT05276817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epic Diode
Description: HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket while activating the diode laser.
Study NCT05276817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP
Description: HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The solution will be in the pocket for 30 seconds, and then removed using sterile gauze and water spray.
Study NCT05276817 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket. The diode laser will not be activated during the sham treatment. Coe-Pak periodontal dressing will be applied to the control quadrant to isolate it.
Study NCT06263478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA034176
Description: IV infusion
Study NCT05039957 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: joint preparation
Description: fixation of fracture with joint preparation
Study NCT05039957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: without joint preparation
Description: fixation of fracture without joint preparation
Study NCT04911569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Description: Cryoneurolysis
Study NCT06048159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tACS
Description: High definition tACS will be applied during speech therapy.
Study NCT06207045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: limb elevation
Description: limb elevation more than 45 degrees
Study NCT06048159 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tACS
Description: Sham high definition tACS will be applied during speech therapy.
Study NCT06576076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management for cannabis abstinence
Description: Those randomized to the abstinence condition (CB-Abst) will be incentivized using an escalating reinforcement schedule for eight weeks of cannabis abstinence.
Study NCT05441267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Oral Tablet
Description: Oral semaglutide 14mg daily (option to reduce to 7mg daily)
Study NCT05441267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral semaglutide
Study NCT06087224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleneonatology
Description: Real-time, two way, audio-video telemedicine connection between the neonatologist located in the regional neonatal intensive care unit (NICU) and the physician located at the community hospital.
Study NCT06669117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERT-002
Description: Route of Administration: Intravenous
Study NCT06304207 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Onsite Maintenance Exercise Training
Description: Participants will receive a 60-minute supervised weekly exercise intervention for 8-weeks.Each 60-minute session will be broken down into a brief 5-minute training on inspiratory muscle training using a Threshold Inspiratory Muscle Trainer (IMT), 5-minute education on self-management of airway clearance and importance of maintaining regular physical activity; a 5-minute warm-up, and 25 minutes of aerobic training. The training intensity will be derived from the distance covered on the six-minute walk test administered at baseline. Training will be performed at 60-85% of VO2 reserve and converted to walking distance and speed using American College of Sports Medicine walking equations for treadmill and overground walking activities or a corresponding rating of perceived exertion (RPE) of 13-16 for non-walking activities. This will be followed by 15-minutes of functional strength training focusing on the lower extremity muscles, and 5 minutes of cool down with stretching exercises.
Study NCT06304207 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Telehealth Maintenance Exercise
Description: Participants in the tele-rehab group will also receive the same intervention as outlined for the onsite group. The mode of aerobic exercise will vary based on availability of equipment in patient homes. The intervention will be delivered remotely via previously researched models using a tablet computer. I-pads will be provided to the participants on a need basis to take home for the duration of the study. Videoconferencing will be via Partners log in enabled Zoom videoconferencing software (San Jose, California, USA) that allows all participants to see and speak to each other. To ensure safety and understanding of equipment operation and the exercise program, the initial training session and establishment of the home exercise program will occur during the initial onsite visit in the clinic at MGH Institute of Health Professions.
Study NCT06440005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGX101
Description: Antibody Drug Conjugate
Study NCT06627335 — intervention group
Intervention type: DRUG
Intervention: Ruxolitinib Cream
Description: Ruxolitinib Cream
Study NCT06627335 — intervention group
Intervention type: DRUG
Intervention: TCS
Description: Topical corticosteroid
Study NCT06692140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)
Description: Percutaneous coronary intervention with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)
Study NCT06692140 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))
Description: Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))
Study NCT04757116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTind
Description: The iTind is implemented for 5-7 days
Study NCT04757116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UroLift
Description: UroLift is a minimally invasive procedure where permanent implants are placed in the prostate.
Study NCT05305560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Tablets
Description: Daily ivermectin tablets intake for 28 days ; 200 mcg/kg on D1 then 100 mcg/kg daily from D2 to D28.
Study NCT05305560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo tablets
Description: Daily placebo tablets intake for 28 days
Study NCT06703034 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological Sampling
Description: The procedures specifically carried out for the study during a single visit are as follows:~* One nasopharyngeal swab for the baseline measurement of the nasal IFN-I score~* Venous blood sample collection in:~  * One yellow tube (5 mL) for anti-interferon antibody measurement~ * One PAXgene tube (2.5 mL) for the baseline IFN score without stimulation~ * Two green heparin tubes (8 mL) for performing immune-functional tests~ * Two large purple tubes (20 mL) for biological collection (if the patient provides specific consent)~ * A total of 35.5 mL of venous blood will be collected for the study during a single visit.~* Stool collection at home by the patient, to be sent by mail to the Northern Biological Resource Center (CRB) of the Hospices Civils de Lyon (HCL) within 10 days after the visit.~* A food frequency questionnaire composed of 159 items measuring the frequency of consumption of foods and drinks over the past 12 months to complement the analysis of the gut microbiota.
Study NCT05716035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Injection
Description: Participants will receive IV tocilizumab
Study NCT04628962 — intervention group
Intervention type: PROCEDURE
Intervention: Collection and Raman analysis of saliva for the database
Description: Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model
Study NCT04593901 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Video and App Review
Description: Scenario Review: The scripts and/or videos will be iteratively reviewed by individual and small groups of home healthcare personnel using Zoom, Microsoft Teams, or similar. The participants will review scripts and/or recordings of the scripts and discuss how well each situation has been represented, how to improve it, and whether it is applicable in their agency.~App Review: Following review of the scenarios, participants will review the smartphone app currently under development, including the control buttons, their placements, and other features of the screen interface. The first 9-12 participants (approximately) will be asked to provide feedback on the app's layout, control locations, and overall appearance. Once suggested changes have been made, the app will then be reviewed by the remaining participants for final review and usability assessment.
Study NCT05493059 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: o Retrospective data collection in database from medical records (clinical, parasitological and therapeutic data)
Study NCT05493059 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: o Administration of two standardized questionnaires by telephone in prospective:~* Dermatology Life Quality Index (DLQI)~* Treatment Satisfaction Questionnaire for Medication (TSQM)
Study NCT05871073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% Injectable Solution
Description: WOUND INFILTRATION AFTER SPINAL SURGERY
Study NCT05871073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone 8mg
Description: WOUND INFILTRATION AFTER SPINAL SURGERY
Study NCT05430373 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GT101
Description: Autologous tumor infiltrating lymphocyte injection
Study NCT06726031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wearing VR glass
Description: The intervention is the application of VR headsets during the procedure for patients who were previously indicated for transradial coronary angiography and were randomized to the VR headset group.
Study NCT05162872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib，Sintilimab
Description: Niraparib 200 mg QD D1-21 Sintilimab 200 mg IV q3W
Study NCT05650372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity resistive exercise
Description: Participants of this group will be applied manual lymphatic drainage and compression bandaging every day of the week, and they will exercise for 25 minutes, three sets of each exercise at 80% intensity of 1 max repetition, 2 days of the week. Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises.Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull-down, bicep curl, triceps extension, lateral raise, and wrist curl.
Study NCT05650372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity resistive exercise
Description: participants in this group will be applied manual lymphatic drainage and compression bandaging every day of the week and they will exercise for 25 minutes, three sets of each exercise at 30% intensity of 1 max repetition 2 days of the week.~Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises. Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull- down, bicep curl, triceps extension, lateral raise, and wrist curl.
Study NCT06391463 — intervention group
Intervention type: OTHER
Intervention: Carriage of MRB ou BC
Description: Study of the epidemiology of the carriage of BMR and BC germs in patients in the neonatology department
Study NCT06726226 — intervention group
Intervention type: OTHER
Intervention: Standard care for preterm infants
Description: Standard care for preterm infants according to the institutional protocol
Study NCT06725823 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suprascapular nerve block group
Description: A volume of (10 ml) of 2% lidocaine (2ml), 3% Mepivacaine (2ml), 1 ml methyl-prednisolone acetate (40 mg) and dextrose 5% (5ml) will be injected to both groups.
Study NCT06725823 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder anterior capsular block group
Description: A volume of (10ml) of 2% lidocaine (2ml), 3% Mepivacaine (2ml), 1 ml methyl-prednisolone acetate (40 mg) and dextrose 5% (5ml) will be injected to both groups.
Study NCT06726330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fimbriectomy Followed by Delayed Oophorectomy (F-DO)
Description: This intervention involves two stages:~1. Fimbriectomy: A preventive surgical procedure that removes the fimbrial end of the fallopian tubes, including adjacent ovarian tissue, while preserving ovarian function to avoid premature menopause.~2. Delayed Oophorectomy: The removal of ovaries, performed at menopause or later, depending on patient preference and clinical guidelines.~   * The F-DO strategy aims to reduce the risk of tubo-ovarian or primary peritoneal carcinoma, which often originates in the fallopian tubes, while minimizing the adverse effects of premature menopause such as cardiovascular disease and osteoporosis
Study NCT06726330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Salpingo-Oophorectomy
Description: This standard surgical intervention involves the removal of both fallopian tubes and ovaries (BSO) to eliminate the risk of tubo-ovarian or primary peritoneal carcinoma. It is typically recommended for women with a genetic predisposition (e.g., BRCA1/2 mutations) around the age of 40-45. While highly effective in preventing cancer, BSO induces premature menopause, which may result in long-term side effects such as increased cardiovascular risk, osteoporosis, and cognitive decline.
Study NCT06726980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextrose 5%
Description: patients will receive 5 % dextrose infusion
Study NCT06726980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 10%
Description: patients will receive 10 % dextrose infusion (25gm/ 250 mL)
Study NCT06726980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: patients will receive infused IV 0.9 % saline
Study NCT06726291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEPA (300mg netupitant/0.5mg palonosetron)
Description: a single dose (capsule) of NEPA (300mg netupitant/0.5 palonosetron) at day 1 for a maximum of 4 cycles
Study NCT06378112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTO®
Description: After teeth extraction, a guided bone regeneration procedure will be performed using a bone graft and a soft collagenated cortical membrane as graft stabilizer. Implant placement surgery will also be performed.
Study NCT06378112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTO®
Description: After teeth extraction, a guided bone regeneration procedure will be performed using a bone graft and a soft collagenated cortical membrane as graft stabilizer. Implant placement surgery will also be performed.
Study NCT06726525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPMC+GlicoPro eyedrops
Description: HPMC+GlicoPro eyedrops, artificial tears for dry eye disease
Study NCT06726525 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxypropyl-methylcellulose
Description: Hydroxypropyl-methylcellulose eyedrops, artificial tears for dry eye disease